STOCK TITAN
  1. Home
  2. Sec-filings
  3. DXCM
  4. [Form 4] DEXCOM INC Insider Trading Activity

Dexcom (DXCM) director receives 5,565 RSU award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ashley Euan A. reported acquisition or exercise transactions in this Form 4 filing.

Dexcom Inc. director Euan A. Ashley received an equity grant of 5,565 restricted stock units (RSUs) on May 28, 2026. The award carries no purchase price and is structured as stock-based compensation, not an open-market share purchase.

According to the terms, 100% of this RSU award will vest on the earlier of the one-year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. After this grant, Ashley holds 12,731 unvested RSUs in total, including 7,166 RSUs granted on October 24, 2025 that are scheduled to vest in tranches through October 24, 2028.

Positive

  • None.

Negative

  • None.
Insider Ashley Euan A.
Role null
Type Security Shares Price Value
Grant/Award Common Stock 5,565 $0.00 --
Holdings After Transaction: Common Stock — 12,731 shares (Direct, null)
Footnotes (1)
  1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement. Included in this number are 12,731 unvested restricted stock units, 5,565 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,166 of which were granted on October 24, 2025 and shall vest through October 24, 2028.
RSUs granted 5,565 units Common Stock RSU award on May 28, 2026
Grant price per RSU $0.00 per unit Reported transaction price per share
Total unvested RSUs after grant 12,731 units Holdings following May 28, 2026 award
New RSU vesting date Earlier of one year from May 28, 2026 or 2027 annual meeting Vesting trigger for 5,565-unit award
Prior RSU grant 7,166 units Granted on October 24, 2025; vesting through October 24, 2028
restricted stock unit financial
"Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share"
A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.
RSU Award financial
"The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary"
Annual Meeting of Stockholders financial
"will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders"
contingent right financial
"restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Ashley Euan A.
(Last)(First)(Middle)
6340 SEQUENCE DRIVE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/28/2026A5,565(1)A$012,731(2)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The RSU Award was granted on May 28, 2026 and 100% of the RSU Award will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Each share is represented by a restricted stock unit (RSU) that represents a contingent right to receive one share of DexCom, Inc. Common Stock upon settlement.
2. Included in this number are 12,731 unvested restricted stock units, 5,565 of which were granted on May 28, 2026 and will vest on the earlier of the one year anniversary of the grant date or the date of DexCom, Inc.'s 2027 Annual Meeting of Stockholders, and 7,166 of which were granted on October 24, 2025 and shall vest through October 24, 2028.
Remarks:
/s/ Jereme M. Sylvain, as Attorney-in-Fact for Dr. Euan Ashley06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Dexcom (DXCM) director Euan A. Ashley report in this Form 4?

Director Euan A. Ashley reported receiving a grant of 5,565 restricted stock units on May 28, 2026. These RSUs are stock-based compensation with no purchase price, increasing his total unvested RSU holdings to 12,731 after the grant.

How do the new Dexcom (DXCM) RSUs for Euan A. Ashley vest?

The 5,565 RSUs granted to Euan A. Ashley vest 100% on the earlier of the one-year anniversary of the May 28, 2026 grant date or DexCom, Inc.'s 2027 Annual Meeting of Stockholders. Vesting must occur before shares of common stock are delivered.

What is Euan A. Ashley’s total Dexcom (DXCM) RSU position after this grant?

Following the May 28, 2026 grant, Euan A. Ashley holds 12,731 unvested restricted stock units. This total includes 5,565 RSUs granted on May 28, 2026 and 7,166 RSUs granted on October 24, 2025 that are scheduled to vest through October 24, 2028.

Does Euan A. Ashley pay a price for the new Dexcom (DXCM) RSUs?

The 5,565 RSUs granted to Euan A. Ashley have a reported per-share price of $0.00. This indicates they are compensation-based awards rather than open-market purchases, with each vested unit settling into one share of DexCom, Inc. common stock.

What earlier Dexcom (DXCM) RSU award to Euan A. Ashley is mentioned?

The filing notes an earlier grant of 7,166 restricted stock units to Euan A. Ashley on October 24, 2025. Those RSUs are scheduled to vest over time, with vesting continuing through October 24, 2028, subject to the award’s terms and conditions.